The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has announced a multi-year $2.5 billion (£1.8bn) fundraising campaign to accelerate the development of next-generation treatment breakthroughs for Parkinson’s disease.
Called All Grit. No Quit., it marks the charity’s first multi‑year fundraising initiative since the campaign launched in 2024.
In that time, it has mobilised a global community of patients, scientists, the biopharmaceutical industry, government and philanthropists to fast-track progress. Donations to the campaign now total more than $1.75 billion, surpassing the halfway mark toward its goal.
Debi Brooks, CEO and co-founder of MJFF, said: “Since our start, the Foundation has galvanized the field to transform Parkinson’s research — building deeper knowledge and stronger collaboration to move faster than ever toward a cure.”
“All Grit. No Quit. reflects our willingness to take bold risks when the science demands it, bringing the full strength of our community to realizing a world without Parkinson’s.”
News of the fundraising campaign comes after actor, advocate and MJFF founder Michael J. Fox was awarded the 2026 Lasker~Bloomberg Public Service Award for his contributions to advancing Parkinson’s research.
Parkinson’s is a progressive neurodegenerative disease that gets worse over time as complex biology unfolds over decades and leads to the destruction of dopamine cells in the brain. There is no treatment that can slow or stop its progression.
Since its founding in 2000, MJFF has grown into the world’s largest nonprofit funder of Parkinson’s research, allocating more than $3 billion globally to jumpstart Parkinson’s drug development and speed progress toward a cure.
Building on this momentum, campaign funds are expected to advance the charity’s Strategic Research Agenda, which has already enabled progress in the field, including the discovery and validation of a new Parkinson’s biomarker in 2023 and approvals of 23 new drugs over the past decade, with 175 more currently in clinical testing.
The foundation also helped secure passage of the National Plan to End Parkinson’s Act in July 2024, the first comprehensive federal legislation dedicated to Parkinson’s research and care.
Todd Sherer, Chief Mission Officer at MJFF, said: “The Parkinson’s drug development pipeline is more active than ever before. Our priority is ensuring the strongest ideas move forward without delay,” said Todd Sherer, PhD, chief mission officer at MJFF.
“This Campaign will enable us to strategically fund at every stage and on parallel paths, shortening the distance between discovery and meaningful benefit for people with Parkinson’s.”